Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Stem Cell Mobilization With Plerixafor + G-CSF In Comparison To Cyclophosphamide + G-CSF and Time-To-Progression After Autologous Stem Cell Transplantation For Multiple Myeloma

Alfred L. Garfall, MD, Andrew Dougherty, Dan T. Vogl, MD, MSCE, Brendan M Weiss, MD, Adam D Cohen, MD, David L. Porter, MD, Una O'Doherty, MD, PhD, Patricia Mangan, CRNP, Kathleen Cunningham, RN, Don L. Siegel, M.D., Ph.D.,, Edward A. Stadtmauer, MD

Blood (2013) 122 (21): 3354.

https://doi.org/10.1182/blood.V122.21.3354.3354

Published: 2013

Journal Articles

A Single-Center Retrospective Comparison of Post-Transplant Outcomes in Patients Receiving VRD Vs. VD Vs. RD As Initial Therapy Prior to ASCT for Newly Diagnosed Multiple Myeloma (MM)

Nathan C Nussbaum, MD, Andrew Dougherty, Dan T. Vogl, MD, MSCE, Brendan M Weiss, MD, David L Porter, MD, E Paul Wileyto, Kathleen Cunningham, Patricia A. Mangan, Brenda K. Shelly, Heather DiFilippo, Edward A. Stadtmauer, MD

Blood (2012) 120 (21): 2042.

https://doi.org/10.1182/blood.V120.21.2042.2042

Published: 2012

Journal Articles

The Optimal Timing for Stem Cell Collection After Induction Therapy for Patients with Multiple Myeloma

Aziz Nazha, Dan T. Vogl, MD, MSCE, Una O'Doherty, MD, PhD, Patricia Mangan, CRNP, Kathleen Cunningham, RN, Selina Luger, MD, David L. Porter, MD, Stephen J. Schuster, Marie Gardler, Mary Sell, Don L. Siegel, MD, PhD, BSc, Edward A Stadtmauer, MD

Blood (2010) 116 (21): 2252.

https://doi.org/10.1182/blood.V116.21.2252.2252

Published: 2010

Journal Articles

Plerixafor and G-CSF Versus Cyclophosphamide and G-CSF for Stem Cell Mobilization in Patients with Multiple Myeloma.

Aziz Nazha, MD, Rachel Cook, MS, MD, Dan T. Vogl, MD, Patricia A. Mangan, APRN, BC, Kimberly Hummel, Kathleen Cunningham, Selina Luger, MD, David Porter, MD, Stephen J. Schuster, MD, Una O'Doherty, Mary Sell, Don L. Siegel, MD, PhD, BSc, Edward A. Stadtmauer, MD

Blood (2009) 114 (22): 2146.

https://doi.org/10.1182/blood.V114.22.2146.2146

Published: 2009

Journal Articles

Second Autologous Stem Cell Transplant (ASCT) as Salvage Therapy for Relapsed Multiple Myeloma.

Rebecca L. Olin, MD, David L. Porter, MD, Selina M. Luger, MD, Stephen J. Schuster, MD, Donald Tsai, MD, PhD, Sunita Nasta, MD, Alexander Perl, MD, Alison W. Loren, MD, Steven Goldstein, MD, Eli Glatstein, MD, Donald L. Siegel, MD, PhD, Dan T. Vogl, MD, Patricia Mangan, CRNP, Kathleen Cunningham, RN, BSN, Edward A. Stadtmauer, MD

Blood (2005) 106 (11): 1170.

https://doi.org/10.1182/blood.V106.11.1170.1170

Published: 2005

Journal Articles

Pegfilgrastim Versus Filgrastim To Accelerate Hematopoietic Recovery after High Dose Melphalan and Autologous Hematopoietic Stem Cell Transplant (ASCT) for Multiple Myeloma.

Rebecca L. Olin, MD, Selina M. Luger, MD, David L. Porter, MD, Stephen J. Schuster, MD, Donald Tsai, MD, Phd, Sunita Nasta, MD, Alexander Perl, MD, Alison W. Loren, MD, Steven Goldstein, MD, Patricia Mangan, CRNP, Vicki Sherry, CRNP, Kathleen Cunningham, RN, Bob Sachs, Kim Hummel, Edward A. Stadtmauer, MD

Blood (2004) 104 (11): 5193.

https://doi.org/10.1182/blood.V104.11.5193.5193

Published: 2004

Journal Articles

Age and Response after Autologous Stem Cell Transplantation (ASCT) Define a Group of Long-Term Event-Free Survivors among Patients (Pts) with Low-Grade Follicular Lymphoma (FL): A Single Institution Experience.

Charalambos Andreadis, MD, Elise A. Chong, Edward A. Stadtmauer, MD, Selina M. Luger, MD, David L. Porter, MD, Donald Tsai, MD, PhD, Sunita Nasta, MD, Rebecca Elstrom, MD, Steven Goldstein, MD, Lisa Downs, RN, Kathleen Cunningham, Kimberly Hummel, Stephen J. Schuster, MD

Blood (2004) 104 (11): 1883.

https://doi.org/10.1182/blood.V104.11.1883.1883

Published: 2004

NARROW

Stem Cell Mobilization With Plerixafor + G-CSF In Comparison To Cyclophosphamide + G-CSF and Time-To-Progression After Autologous Stem Cell Transplantation For Multiple Myeloma

A Single-Center Retrospective Comparison of Post-Transplant Outcomes in Patients Receiving VRD Vs. VD Vs. RD As Initial Therapy Prior to ASCT for Newly Diagnosed Multiple Myeloma (MM)

The Optimal Timing for Stem Cell Collection After Induction Therapy for Patients with Multiple Myeloma

Plerixafor and G-CSF Versus Cyclophosphamide and G-CSF for Stem Cell Mobilization in Patients with Multiple Myeloma.

Second Autologous Stem Cell Transplant (ASCT) as Salvage Therapy for Relapsed Multiple Myeloma.

Pegfilgrastim Versus Filgrastim To Accelerate Hematopoietic Recovery after High Dose Melphalan and Autologous Hematopoietic Stem Cell Transplant (ASCT) for Multiple Myeloma.

Age and Response after Autologous Stem Cell Transplantation (ASCT) Define a Group of Long-Term Event-Free Survivors among Patients (Pts) with Low-Grade Follicular Lymphoma (FL): A Single Institution Experience.

Email alerts

ASH Publications

American Society of Hematology

Stem Cell Mobilization With Plerixafor + G-CSF In Comparison To Cyclophosphamide + G-CSF and Time-To-Progression After Autologous Stem Cell Transplantation For Multiple Myeloma

A Single-Center Retrospective Comparison of Post-Transplant Outcomes in Patients Receiving VRD Vs. VD Vs. RD As Initial Therapy Prior to ASCT for Newly Diagnosed Multiple Myeloma (MM)

The Optimal Timing for Stem Cell Collection After Induction Therapy for Patients with Multiple Myeloma

Plerixafor and G-CSF Versus Cyclophosphamide and G-CSF for Stem Cell Mobilization in Patients with Multiple Myeloma.

Second Autologous Stem Cell Transplant (ASCT) as Salvage Therapy for Relapsed Multiple Myeloma.

Pegfilgrastim Versus Filgrastim To Accelerate Hematopoietic Recovery after High Dose Melphalan and Autologous Hematopoietic Stem Cell Transplant (ASCT) for Multiple Myeloma.

Age and Response after Autologous Stem Cell Transplantation (ASCT) Define a Group of Long-Term Event-Free Survivors among Patients (Pts) with Low-Grade Follicular Lymphoma (FL): A Single Institution Experience.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only